Skip to main content

Table 1 Clinical characteristics of pediatric posterior fossa ependymoma

From: Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma

CharacteristicsValue (%)
Demographics
 No. of patients45
 Age, years, median (range)4 (1–17)
 Gender, (female/male)12/33
 Tumor size, cm, median (range)4.7 (2.3–19.5)
 Extent of surgery, GTR, n (%)21 (46.7)
 Radiotherapy, yes, n (%)29 (64.4)
 Chemotherapy, yes, n (%)12 (26.7)
Histology, n (%)
 WHO II10 (22.2)
 WHO III35 (77.8)
Ki-67 index, n (%)
 < 20%20 (44.4)
 ≥ 20%25 (55.6)
Molecular subgroups, n (%)
 EPN_PFA35 (77.8)
 EPN_PFB10 (22.2)
Chromosome 1q
 Gain16 (35.6)
 No gain29 (64.4)
5hmC/(C + mC) × 100%, median (range)0.127 (0.028–0.341)
5mC/(C + mC) × 100%, mean ± SD3.664 ± 0.426
Recurrence, n (%)25 (55.6)
Death during follow-up, n (%)23 (51.1)
Follow-up period, months, median (range)38 (6–60)
  1. GTR gross total resection, 5hmC 5- hydroxymethylcytosine, 5mC 5-methylcytosine, C cytosine, EPN_PFA Group A posterior fossa ependymoma, EPN_PFB Group B posterior fossa ependymoma